An Rh-105 complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates

Nuclear Medicine and Biology

Volumn 23, Issue 1, 1996, Pages 33-40

  Venkatesh, M ^a   Goswami, N ^b   Volkert, W A ^c,d   Schlemper, E O ^b   Ketring, A R ^b   Barnes, C L ^b   Jurisson, S ^b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b UNIVERSITY OF MISSOURI   (United States)

^c University of Missouri   (United States)

^d HS Truman Memorial VA Hospital   (United States)

Author keywords

Radiotherapy; Rhodium (III) tetrathioether complex; Rhodium 105

Indexed keywords

CHELATING AGENT; RHODIUM 105; TETRATHIACYCLOHEXADECANE DIOL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; RADIOISOTOPE THERAPY;

EID: 0030041725     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02012-8     Document Type: Article

References (43)

1. Addison A. W., Guillard R. D. and Vaughan H. (1973) Polography of some rhodium(III) complexes. J. Chem. Soc., Dalton Trans., 1187-1193.
2. Alison M. R. and Wright N. A. (1993) Growth factors and growth factor receptors. Br. J. Hosp. Med. 49, 774-783.
3. Bakker W. H., Albert R., Bruns C., et al. (1991) [Indium-111-DTPA-D-Phe-1] octreotide, a potential radiopharmaceutical for imaging somatostin receptor positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci. 49, 1583-1591.
4. Bartfai T., Firsone G. and Lonjel U. (1992) Galanin and galania antagonists: Molecular and biochemical perspectives. TIPS 13, 312-318.
5. Basolo F. and Pearson R. G. (1967) Mechanisms of Inorganic Reactions. Wiley, New York.
6. Bhattacharya P. K. (1980) Electronic spectra of some rhodium(III) complexes of saturated cyclic tetramines. J. Chem. Soc., Dalton Trans. 810-812.
7. 3 = 1,5,9,13-tetra thiocyclohexadecane). J. Chem. Soc., Dalton Trans. 1675-1680.
8. 4 = 1,4,10,13 tetrathia-7,16-diaza cyclocladecane). Polyhedron 9, 2925-2929.
9. - equilibria. J. Chem. Soc. 5931-5934.
10. - systems. J. Chem. Soc. 286.
11. 4 = 1,10 dimethyl-1,10-diaza-4,7,13,16-tetrathiacyclocltedecane). Polyhedron 11, 3165-3172.
12. Coy D. H., Munjan Z., Rossowski W. J., et al. (1992) Development of a patent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat. Peptides 13, 775-781.
13. DiZio J. P., Fiaschi R., Davison A., Jones A. G. and Katzenellenbogen J. A. (1991) Progestin-rhenium complexes: Metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy. Bioconjugate Chem. 2, 353-366.
14. Eckelman W. C., Grisson M., Conklin J., Rzeszotarski W. J., Gibson R. E., Francis B. E., Jagoda E. M., Eng R. and Reba R. C. (1984) In vivo competition studies with analogues of 3-quinuclidinyl benzilate. J. Pharm. Sci. 4, 529-534.
15. Efe G. E. Pillai M. R. A., Schlemper E. O. and Troutner D. E. (1991) Rhodium complexes of two bidentate secondary amine onime ligands and application to the labelling of proteins. Polyhedron 10, 1617-1624.
16. Fischman A. F., Babich J. W. and Strauss H. W. (1993) A ticket to ride: Peptide radiopharmaceuticals. J. Nucl. Med. 34, 2253-2263.
17. Furlani C. and Luciani M. L. (1968) Complexes of dithiocarbonylic acids. Inorg Chem. 7, 1586-1592.
18. Gabe E. J., Le Page Y., Charland J.-P., Lee F. L. and White P. S. (1989) Full system reference. J. Appl. Cryst. 22, 384-387.
19. Gillard R. D., Osborn J. A. and Wilkinson G. (1965) Catalytic approaches to complex compounds of rhodium(III). J. Chem. Soc. 1951-1965.
20. Gillard R. D. and Wilkinson G. (1964) Complexes of rhodium(III) with chlorine and pyridine. J. Chem. Soc. 1224-1228.
21. Grazman B. and Troutner D. E. (1988) Rhodium-105 as a potential therapeutic agent. Appl. Radiat. Isotopes 39, 257-260.
22. Hancock R. D. and Martell A. E. (1989) Ligand design for selective complexation of metal ions in aqueous solution. Chem. Rev. 89, 1875-1914.
23. Hnatowich D. J. (1990) Antibody radiolabeling: Problems and promises. Nucl. Med. Biol. 17, 49-55.
24. Jardine F. H. and Sheridan P. S. (1987) In Comprehensive Coordination Chemistry, Vol. 4 (Edited by Wilkinson G., Gillaro R. D. and McLeverty J. A.), pp. 901-1096 Pergamon Press, Tarrytown, NY.
25. Johnson C. K. (1976) ORTEP - A Fortran Thermal Ellipsoid Plot Program, Technical Report ORNL-5138, U.S. Department of Energy, Oak Ridge, TN.
26. Kelly K., Kane M. A. and Bunn P. A. (1991) Growth factors in lung cancers: Possible etiologic role and clinical target. Med. Ped. Oncol. 19, 449-458.
27. Kozak R. W., Roubitschek A., Mirzadeh S., et al. (1989) Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 labeled monoclonal antibodies: Clinical factors in determining in vivo survival and organ toxicity. Cancer Res. 49, 2639-2644.
28. 111In-octreotide scintigraphy in oncology. Metabolism 41(Suppl.), 83-86.
29. Kung H. F. (1991) Overview of radiopharmaceuticals for diagnosis of central nervous system disorders. Crit. Rev. in Lab Sci. 28, 269-286.
30. Larson S. M. (1990) Improved tumor targeting with radiolabelled, recombinant single-chain, antigen binding protein. J. Nat. Cancer Inst. 82, 1173-1174.
31. Lo J. M., Pillai M. R. A., John C. C. and Troutner D. E. (1990) Radiochemical purity evaluation of rhodium-105 complexes by magnesium oxide. Int. J. Radiat. Appl. Instrum., Part A, Appl. Radiat. Isotopes 41, 103-105.
32. Mausner L. V., Straub R. F. and Srivastava S. C. (1988) Production and use of prospective radionuclides for radioimmunotherapy. In Radiolabeled Monoclonal Antibodies for Imaging and Therapy (Edited by Srivastava S. C.), pp. 149-163. Plenum Publishing Corp., New York.
33. v derived from pancarcinoma monoclonal antibody CC49. Cancer Res. 51, 6363-6371.
34. Rund, J. V., Basolo F. and Pearson R. G. (1964) Catalysis of substitution reactions of rhodium(III) complexes. The reaction of aquapentachlororhodate (III) ion wirh pyridine. Inorg. Chem. 3, 658-661.
35. Schubiger P. A. and Hasler P. H. (1986) Radionuclides for Therapy. Hoffman-LaRoche & Co., Ltd., Basel, Switzerland.
36. Selikson M., Gibson R. E., Eckelman W. C. and Reba R. C. (1980) Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. Anal. Biochem. 108, 64-71.
37. Silverstein R. M., Bassler G. C. and Morrill T. C. (1991) Spectrometric Identification of Organic Compounds. 5th ed. John Wiley & Sons, New York.
38. Travis K. and Busch D. H. (1974) Cobalt(III) and rhodium(III) complexes of cyclic tetradentate thioethers. Inorg. Chem. 13, 2591-2598.
39. Troutner D. E. (1987) Chemical and physical properties of radionuclides. Int. J. Radiat. Appl. Inst., Part B. Nucl. Med. Biol. 14, 171-176.
40. Verbruggen A. M. (1990) Radiopharmaceuticals: State of the art. Eur. J. Nucl. Med. 17, 346-364.
41. Volkert W. A., Goeckeler, W. F., Ehrhardt G. J. and Ketring A. R. (1991) Therapeutic radionuclides production and decay property considerations. J. Nucl. Med. 32, 174-185.
42. Woll P. J. (1991) Neuropeptide growth factors and cancers. Br. J. Cancer 63, 469-475.
43. v and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408.